Rituxan is a type of therapy called B-cell therapy. Unlike anti-TNFs, B-cell therapy targets a type of immune cell called a B-cell. Overactive B-cells are believed to play a role in the symptoms and joint damage of RA.
An anti-TNF, or anti-tumor necrosis factor, is usually the first biologic given upon diagnosis with RA.* Many people have success with anti-TNFs. But if these treatments stop working well, some may decide to make a change after talking with their doctor.
As you may know, sometimes people with RA need to try a few treatments before finding one that’s right for them. The key is to closely track how well a treatment is working for you and to figure out with your doctor when a different approach might be needed. Some signs it may be time for a change include:
*Common anti-TNF treatments are Cimzia® (certolizumab pegol), Enbrel® (etanercept), Humira® (adalimumab), Remicade® (infliximab), and Simponi® (golimumab). All trademarks are the property of their respective owners. All treatments are prescription only.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.